A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Trial Profile

A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs LIK 066 (Primary)
  • Indications Overweight; Polycystic ovary syndrome
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 24 May 2017 Planned initiation date changed from 6 Jul 2017 to 29 Jun 2017.
    • 17 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top